Private Wealth Asset Management LLC Makes New $1.67 Million Investment in Illumina, Inc. $ILMN

Private Wealth Asset Management LLC acquired a new position in Illumina, Inc. (NASDAQ:ILMN – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,094 shares of the life sciences company’s stock, valued at approximately $1,668,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of ILMN. BlackRock Inc. bought a new stake in Illumina during the second quarter valued at about $3,374,423,000. Primecap Management Co. CA bought a new position in shares of Illumina in the second quarter worth about $617,981,000. Ninety One UK Ltd lifted its position in shares of Illumina by 37,920.0% during the 3rd quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock valued at $372,198,000 after buying an additional 1,356,397 shares in the last quarter. Jupiter Topco LLC bought a new position in shares of Illumina during the 2nd quarter valued at approximately $358,652,000. Finally, Wellington Management Group LLP grew its stake in shares of Illumina by 190.1% during the 2nd quarter. Wellington Management Group LLP now owns 1,812,928 shares of the life sciences company’s stock valued at $318,767,000 after acquiring an additional 1,188,004 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina News Roundup

Here’s some of the latest news about ILMN:

  • Positive Sentiment: Illumina’s BioInsight AI Lab won the 2026 Virtual Cell Challenge using its Billion Cell Atlas and CellularAI algorithm. The result highlights the company’s data and AI capabilities, although the financial impact is not yet clear. Illumina Wins Virtual Cell Challenge, Powered by Billion Cell Atlas
  • Positive Sentiment: A proposed Senate bill would clarify Medicaid coverage for whole-genome and whole-exome sequencing for certain children. If enacted, broader coverage could support demand for sequencing, but the proposal remains early-stage. Genomic Answers for Children’s Health Act of 2026
  • Negative Sentiment: Voluntary Class II recalls linked to cybersecurity vulnerabilities in several diagnostic sequencing instruments have heightened concerns about operational risk and data integrity. The report also notes recent weakness in the shares, adding to near-term pressure. Is Illumina Undervalued Following Its Cybersecurity Recalls?

Insider Activity at Illumina

In related news, Director Keith A. Meister sold 98,833 shares of the company’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $216.87, for a total transaction of $21,433,912.71. Following the completion of the transaction, the director owned 208,826 shares in the company, valued at approximately $45,288,094.62. This represents a 32.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Scott D. Ericksen sold 267 shares of the company’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $217.76, for a total transaction of $58,141.92. Following the transaction, the chief accounting officer owned 14,029 shares of the company’s stock, valued at approximately $3,054,955.04. This represents a 1.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,201,292 shares of company stock worth $270,151,290. Company insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ILMN shares. TD Cowen increased their target price on shares of Illumina from $210.00 to $270.00 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Stifel Nicolaus lifted their price target on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a report on Friday, July 31st. Leerink Partners upped their price target on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Guggenheim upped their price target on shares of Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Finally, Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 1st. Nine analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Illumina currently has a consensus rating of “Hold” and a consensus target price of $243.72.

View Our Latest Report on Illumina

Illumina Price Performance

NASDAQ:ILMN opened at $192.82 on Friday. The business’s 50-day simple moving average is $248.27 and its two-hundred day simple moving average is $181.05. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35. The stock has a market cap of $29.15 billion, a PE ratio of 37.71, a P/E/G ratio of 2.69 and a beta of 1.46. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57.

Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same period in the previous year, the firm earned $1.34 EPS. The firm’s revenue was up 4.2% compared to the same quarter last year. As a group, analysts forecast that Illumina, Inc. will post 5.43 EPS for the current fiscal year.

Illumina Company Profile

(Free Report)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

See Also

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.